Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary E.R. O'Brien, Luis G Paz-Ares, Sandrine I. Marreaud et al. · The Lancet Oncology · 2022

Cited by 774 works. doi:10.1016/s1470-2045(22)00518-6

Authors

References